For research use only. Not for therapeutic Use.
Orally active cell-permeable inhibitor of human β-secretase (BACE-1); potential agent to treat Alzheimer’s Disease
| Catalog Number | M089346 |
| CAS Number | 1262036-49-6 |
| Molecular Formula | C18H16F2N4O2S.HCl |
| Purity | ≥95% |
| IUPAC Name | N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide;hydrochloride |
| InChI | InChI=1S/C18H16F2N4O2S.ClH/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18;/h1-6,10H,7-9H2,(H2,21,24)(H,23,25);1H/t10-,18-;/m0./s1 |
| SMILES | C1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N.Cl |
| Reference | M Townsend. When will Alzheimer’s disease be cured? A pharmaceutical perspective. J. Alzheimers Dis. 2011, 24 (Suppl 2), 43-52.
P May et al. Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer’s disease. Alzheimer’s & Dementia 2012, 8(4), 95.
B Willis et al. Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta. Alzheimer’s & Dementia 2012, 8(4), 582.
F Martenyi et al. BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs). Alzheimer’s & Dementia 2012, 8(4), 583. |
